Tags

Type your tag names separated by a space and hit enter

Antiviral treatment of COVID-19
Turk J Med Sci. 2020 04 21; 50(SI-1):611-619.TJ

Abstract

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections.

Authors+Show Affiliations

Department of Infectious Disease and Clinical, Microbiology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, TurkeyDepartment of Infectious Disease, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32293834

Citation

Şimşek Yavuz, Serap, and Serhat Ünal. "Antiviral Treatment of COVID-19." Turkish Journal of Medical Sciences, vol. 50, no. SI-1, 2020, pp. 611-619.
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020;50(SI-1):611-619.
Şimşek Yavuz, S., & Ünal, S. (2020). Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences, 50(SI-1), 611-619. https://doi.org/10.3906/sag-2004-145
Şimşek Yavuz S, Ünal S. Antiviral Treatment of COVID-19. Turk J Med Sci. 2020 04 21;50(SI-1):611-619. PubMed PMID: 32293834.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiviral treatment of COVID-19 AU - Şimşek Yavuz,Serap, AU - Ünal,Serhat, Y1 - 2020/04/21/ PY - 2020/04/13/received PY - 2020/04/15/accepted PY - 2020/4/16/entrez PY - 2020/4/16/pubmed PY - 2020/4/23/medline KW - Covid-19 KW - Sars-CoV-2 KW - antiviral SP - 611 EP - 619 JF - Turkish journal of medical sciences JO - Turk J Med Sci VL - 50 IS - SI-1 N2 - Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human infections. SN - 1303-6165 UR - https://www.unboundmedicine.com/medline/citation/32293834/Antiviral_treatment_of_COVID_19 L2 - https://doi.org/10.3906/sag-2004-145 DB - PRIME DP - Unbound Medicine ER -